Humacyte Inc (NASDAQ:HUMA) price on Wednesday, April 30, rose 1.40% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.45.
A look at the stock’s price movement, the close in the last trading session was $1.43, moving within a range at $1.35 and $1.45. The beta value (5-Year monthly) was 1.621. Turning to its 52-week performance, $9.97 and $1.15 were the 52-week high and 52-week low respectively. Overall, HUMA moved -14.96% over the past month.
Humacyte Inc’s market cap currently stands at around $224.92 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-27.
Turning to the stock’s technical picture we see that short term indicators suggest on average that HUMA is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 1 recommend HUMA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
HUMA’s current price about -0.38% and -38.66% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 36.92, while 7-day volatility ratio is 5.35% and 11.62% in the 30-day chart. Further, Humacyte Inc (HUMA) has a beta value of 1.64, and an average true range (ATR) of 0.18. Analysts have given the company’s stock an average 52-week price target of $6, forecast between a low of $5 and high of $10. Looking at the price targets, the low is -244.83% off current price level while to achieve the yearly target high, price needs to move -589.66%. Nonetheless, investors will most likely welcome a -313.79% jump to $6 which is the analysts’ median price.
If we refocus on Humacyte Inc (NASDAQ:HUMA), historical trading data shows that trading volumes averaged 2.39 over the past 10 days and 3.55 million over the past 3 months. The company’s latest data on shares outstanding shows there are 130.03 million shares.
The 18.94% of Humacyte Inc’s shares are in the hands of company insiders while institutional holders own 27.68% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 26.09 million on 2025-04-15, giving us a short ratio of 4.27. The data shows that as of 2025-04-15 short interest in Humacyte Inc (HUMA) stood at 2065.0 of shares outstanding, with shares short falling to 26.6 million registered in 2025-03-14. Current price change has pushed the stock -71.29% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the HUMA stock continues to rise going into the next quarter.
